SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Burris HA,Moore MJ,Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 2001; 15: 24032413.
  • 2
    Berlin JD,Catalano P,Thomas JP. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002; 20: 32703275.
  • 3
    Oettle H,Richards D,Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005; 16: 16391645.
  • 4
    Louvet C,Labianca R,Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005; 23: 35093516.
  • 5
    Van Cutsem E,van de Velde H,Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004; 22: 14301438.
  • 6
    Moore MJ,Goldstein D,Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 19601966.
  • 7
    Miwa M,Ura M,Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998; 34: 12741281.
  • 8
    Cartwright TH,Cohn A,Varkey JA. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol. 2002; 20: 160164.
  • 9
    Herrmann R,Bodoky G,Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Res. and the Central European Cooperative Oncology Group. J Clin Oncol. 2007; 25: 22122217.
  • 10
    Cunningham D,Chau I,Stocken D, et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Presented at the European Conference (ECCO), Paris, France, October 30-November 3, 2005.
  • 11
    Faivre S,Raymond E,Woynarowski JM, et al. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol. 1999; 44: 117123.
  • 12
    Diaz-Rubio E,Evans TR,Tabernero J, et al. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol. 2002; 13: 558565.
  • 13
    Kornmann M,Kakler H,Butzer U, et al. Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases. Anticancer Res. 2000; 20: 32593264.
  • 14
    Poplin E,Levy DE,Berlin J, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). ASCO Annual Meeting. J Clin Oncol. 2006; 24(18S pt I): LBA4004.
  • 15
    Mitry E,Ducreux M,Ould-Kaci M, et al. Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. Gastroenterol Clin Biol. 2006; 30: 357363.
  • 16
    Thall PF,Simon R. A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials. Control Clin Trials. 1994; 15: 463481.
  • 17
    Oettle H,Pelzer U,Stieler J, et al. Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol. 2005; 23(16S). Abstract 4031.
  • 18
    Nakachi K,Furuse J,Ishii H,Suzuki E,Yoshino M. Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol. 2007; 37: 114120.
  • 19
    Ulrich-Pur H,Raderer M,Kornek GV, et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer. 2003; 88: 11801184.
  • 20
    Milella M,Gelibter A,Di Cosimo S, et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer. 2004; 101: 133138.
  • 21
    Cantore M,Rabbi C,Fiorentini G, et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology. 2004; 67: 9397.
  • 22
    Jacobs AD,Burris HA,Rivkin S, et al. A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer. Report from a North-American multi-center study. J Clin Oncol. 2004; 22(14S). Abstract 4013.
  • 23
    Androulakis N,Syrigos K,Polyzos A, et al. Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest. 2005; 23: 912.
  • 24
    Tsavaris N,Kosmas C,Skopelitis H, et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Invest New Drugs. 2005; 23: 369375.
  • 25
    Demols A,Peeters M,Polus M, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer. 2006; 94: 481485.
  • 26
    Reni M,Pasetto L,Aprile G, et al. Raltitrexed-eloxantin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer. 2006; 94: 785791.
  • 27
    Ignatiadis M,Polyzos A,Stathopoulos GP, et al. A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology. 2006; 71: 159163.
  • 28
    Boeck S,Weigang-Kohler K,Fuchs M, et al. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann Oncol. 2007; 18: 745751.
  • 29
    Kulke MH,Blaszkowsky LS,Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007; 25: 47874792.
  • 30
    Boeck S,Heinemann V. The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer. Future Oncol. 2008; 4: 4150.
  • 31
    Schrag D,Archer L,Wang X, et al. A patterns-of-care study of post-progression treatment (Rx) among patients (pts) with advanced pancreas cancer (APC) after gemcitabine therapy on Cancer and Leukemia Group B (CALGB) study #80303. ASCO Annual Meeting Proceedings. J Clin Oncol. 2007; 25( suppl pt 1): 4524.